Accepted Articles, Accepted manuscript online: 7 NOV 2013
Article type: Solicited Review
Received date: 27-Sep-2013
Accepted date: 18-Oct-2013
Chun-Jen Liu, M.D., Ph.D.
Graduate Institute of Clinical Medicine, Department of Internal Medicine, and
Hepatitis Research Center, National Taiwan University College of Medicine and
National Taiwan University Hospital, Taipei 100, Taiwan
There are no potential conflicts of interest to declare.
e-mail address: email@example.com
Acknowledgements: The work was supported by grants from the National Taiwan
University Hospital; Department of Health, Executive Yuan, Taiwan; and Taiwan Liver
Disease Consortium (TLC), National Research Program for Biopharmaceuticals (NRPB),
Running title: Treatment of dual HCV/HBV
Electronic word count: 2642 (From introduction to reference
*Correspondence and reprint requests to:
Chun-Jen Liu, M.D., Ph.D.
Professor, Graduate Institute of Clinical Medicine
National Taiwan University College of Medicine
1 Chang-Te Street, Taipei 10002, TAIWAN
Tel.: 886-2-23123456 ext 67503
Dual infection • hepatitis B virus • hepatitis C virus • interferon • pegylated
interferon • ribavirin • sustained virological response • HBsAg clearance
Dual hepatitis C virus (HCV)/hepatitis B virus (HBV) infection is not uncommon in HCV or HBV endemic areas and among subjects at risk of parenteral transmission. In patients dually infected with hepatitis C and B, the disease manifestations are usually more severe than those with either virus infection. In the past decade, the following issues have been resolved. In dually infected patients with active hepatitis C, combined pegylated interferon alfa plus ribavirin was effective, the treatment outcomes being similar to patients with HCV mono-infection. During long-term follow-up, the HCV response was sustained in around 97% of patients; and the long-term outcomes including the development of HCC and liver-related mortality were improved. However, several clinical issues remain to be resolved. First, host and viral factors influencing the long-term outcomes and treatment options in patients with dual HCV/ HBV infection await further studies. Second, about 60% of dually infected patients with baseline undetectable serum HBV DNA levels develop HBV reactivation after the start of treatment. How to prevent and treat HBV reactivation should be clarified. Third, about 30% of dually infected patients lose HBsAg at 5 years after the end of combination therapy; the mechanisms need further investigations. Fourth, the optimal treatment strategies for dually infected patients with active hepatitis B or established cirrhosis should be explored in future clinical trials. Finally, the role of new direct-acting antiviral (DAA)-based therapy for the treatment of patients with dual HCV/HBV infection also remains to be evaluated.
Worldwide, the majority of hepatitis C patients have chronic hepatitis C virus (HCV) monoinfection. In areas or countries where hepatitis B virus (HBV) infection is endemic, such as Taiwan, it is not uncommon to encounter patients infected with both hepatitis viruses [1-3]. In the past decade, the following issues regarding dual HCV/HBV infection were resolved. First, epidemiologic studies demonstrated that in patients with dual chronic hepatitis C and B, the disease manifestations are usually more severe than those with either virus infection [4-6]. In support of these data, a large follow-up study on Taiwanese patients demonstrated the combined effect of HCV and HBV infection on the progression of chronic liver disease . Therefore, patients dually infected with hepatitis C and B should be followed more closely and require effective treatment. Second, recent studies supported that selection of priority virus to be treated in patients with dual chronic hepatitis C/B can be determined by the viral activity of either one. In dually infected patients with active hepatitis C, pegylated interferon (Peg-IFN) alfa plus ribavirin (RBV) was effective to achieve HCV RNA clearance, i.e. sustained virologic response (SVR) . Post-treatment 5-year follow-up demonstrated that the durability of HCV SVR was maintained in 97% . Besides, using Peg-IFN-based therapy, HBsAg seroclearance was also documented in 5.4% of dually infected patients per year. Third, in addition to the control of viral infection, a large retrospective population-based study well demonstrated that the use of Peg-IFN plus RBV combination therapy significantly reduced the risk of hepatocellular carcinoma (HCC) (hazard ratio [HR] 0.75), liver-related mortality (HR 0.45), and all-cause mortality (HR 0.39) . All these data were presented and certain unresolved issues will be discussed in this mini-review.
Clinical significance of dual chronic hepatitis C and B
Several cross-sectional or retrospective, hospital- or community-based, studies demonstrated that in patients with dual chronic hepatitis C and B, the disease manifestations are usually more severe than or at least as severe as those with either chronic HCV or HBV infection [1-6]. A prospective large cohort from Taiwan confirmed that the risk of developing HCC was higher in patients with dual chronic HCV/HBV infection than that with either virus infection . The cumulative lifetime (age 30 to 75 years) incidences of HCC for men and women positive for both HBsAg and anti-HCV were 38.35% and 27.40%; for those positive for HBsAg only, 27.38% and 7.99%; for those positive for anti-HCV only, 23.73% and 16.71%; and for those positive for neither, 1.55% and 1.03%, respectively.
Patients with dual HCV/HBV infection may exhibit a wide spectrum of virological profiles during the long-term follow-up. Because most available data were based on cross-sectional observations, the possibility that HCV and HBV can alternate their dominance during co-infection cannot be excluded. In Italy, a longitudinal follow-up study in Italy revealed the patterns and dynamics of virological dominance in these cases . Of 103 untreated HBV/HCV dually infected patients, active infection with both HBV and HCV was revealed in 24 (23%) cases, inactive infection by both viruses was seen in 15 (15%) cases, active HBV/inactive HCV was seen in 15 (15%) cases, and active HCV/inactive HBV was found in 49 (48%) cases. During 12-month follow-up, dynamic virological profiles characterized by fluctuation of HBV and/or HCV viremia levels were documented in 32 subjects (31%). Nguyen et al characterized HBV/HCV dual infection in a large multiethnic study in the United States . They found that dual infected patients exhibited very little HBV/HCV codominance at baseline and throughout follow-up; patients had either HBV viremia with low or absent HCV RNA or detectable HCV RNA with low or absent HBV DNA. Asian ethnicity was predictive of HBV dominance after adjusting for sex, age, and baseline ALT elevation; and HCV dominance with undetectable HBV DNA is more common in non-Asian individuals. Based on these observational data, careful longitudinal follow-up of serum HBV DNA and HCV RNA levels is essential before the diagnosis of the viral dominance. These viral interactions will very likely influence the therapeutic strategies in dually infected patients
Treatment of HCV and HBV dual infection: Determine the virus(es) to be treated
Active hepatitis C is found in more than 50% of dually infected patients . Besides, HCV can be successfully eradicated in at least 70% of patients with chronic HCV mono-infection using combination therapy of Peg-IFN and RBV in Asian-Pacific region . Accordingly, HCV seems to be the priority target to be managed in dually infected patients with active hepatitis C (Figure 1). .
Treatment of hepatitis C in dual hepatitis C/B patients with active hepatitis C:
IFN plus ribavirin
Early small care series found that interferon (IFN) alone was not effective in the clearance of HCV RNA in dually infected patients . Later on, we demonstrated that combination therapy of conventional IFN plus RBV had better, albeit not satisfactory, HCV SVR rates [14-16].
Peg-IFN plus ribavirin
In the treatment of patients with HCV mono-infection, Peg-IFN in combination with RBV becomes the standard of care in the past decade. Our recent data supported that the efficacy of treatment of dually infected patients may also be enhanced through Peg-IFN plus RBV . For genotype 1 infection, HCV SVR at 6 months after end of treatment was 72.2% in dually infected patients and was 77.3% in mono-infected patients. For genotype 2/3 infections, SVR was 82.8% in dually infected patients and 84.0% in mono-infected patients. The results confirmed that replacing conventional IFN with Peg-IFN in the combination therapy significantly improved the SVR rate of HCV genotype 1 in the dually infected patients. In addition to our multicenter trial, a satisfactory HCV SVR rate was also documented is another 2 small series of patients with dual HBV/HCV infection using Peg-IFN alfa plus RBV combination therapy [17,18]. The results are summarized in Figure 2.
Durability of HCV responses post-treatment
Previous studies suggested that hepatitis C may relapse in 0.9~10% of simple chronic hepatitis C patients who initially obtained virologic response after end of the treatment. To address this issue, the durability of hepatitis C clearance in these dually infected patients was investigated by a 5-year follow-up study . Our results revealed that after a median follow-up of 4.6± 1.0 years, only 6 (2.6%) of the 232 patients achieving SVR developed HCV RNA reappearance, including 5 HCV genotype 1/HBV coinfected patients and 1 HCV genotype 2/3 monoinfected patient. These data suggested that Peg-IFN alfa and ribavirin therapy provided a good durability of HCV SVR.
HBV responses and clearance of HBsAg
Virological response (VR) of HBV to Peg-IFN and the potential risk for reactivation of HBV DNA during treatment of co-existing chronic hepatitis C are two major clinical concerns that needed to be addressed in dually infected patients receiving effective anti-HCV therapy . HBsAg clearance at 6 months after end of therapy was found in 18 (11.2%) of the 161 dually infected patients. During 5-year post-treatment follow-up, the rate of HBsAg seroclearance was 5.4% per year, reaching 30% at the end of follow-up [9,19].
Improvement of long-term outcomes post-treatment
Reduction of development of HCC and improvement of overall survival: A population-based study in Taiwan
Whether Peg-IFN and ribavirin combination therapy could reduce the risk of HCC or improve survival in HCV/HBV dually infected patients was evaluated in a large population-based cohort from Taiwan . We examined the risk of HCC, mortality, and adverse events in 1,096 treated and 17,562 untreated HCV/HBV dually infected patients. After adjustment, combination therapy significantly reduced the risk of HCC (hazard ratio [HR] 0.75, 95% confidence interval [95%CI] 0.58–0.96), liver-related mortality (HR 0.45, 95% CI 0.35–0.57), and all-cause mortality (HR 0.39, 95%CI 0.32–0.48) (Table 1). Nevertheless, the underlying HBV infection was still a risk factor for HCC and mortality after treatment. Our data demonstrated that combination therapy decreased the risk of developing HCC and improved survival in HCV/HBV dually infected patients [10,20].
Prevention and management of HBV reactivation
In our treatment cohort, of 76 patients with pre-treatment serum HBV DNA <200 IU/mL, reappearance of HBV DNA was found in 47 (61.8%) patients . These patients should be monitored regularly and prompt anti-HBV therapy should be implemented if clinically indicated.
Host and viral factors affecting natural and treatment outcomes of patients with dual chronic HCV/HBV
The outcomes of chronic viral hepatitis B or C are likely to be influenced by certain host and viral genomic factors. The impacts of the viral factors and host factors await further investigations. Furthermore, the treatment outcomes using similar Peg-IFN/RBV combination regimen in other ethnicity and populations with different chronologic sequence of HCV and HBV infection should also be evaluated .
Factors associated with seroclearance of HBsAg
In our treatment cohort, only baseline low pre-treatment serum HBsAg level correlated significantly with sustained HBsAg seroclearance (P<0.05) [8,9,21]. In another study, we identified the host genetic factors associated with spontaneous HBsAg seroclearance; rs9277535 polymorphism for HLA-DPB1 region was associated with HBsAg seroclearance in CHB patients . Host and viral factors potentially affecting treatment-induced seroclearance of HBsAg in dually infected patients are under active investigations.
Role of new direct-acting antiviral (DAA)-based therapy
Currently, DAA-based triple therapy is the standard-of-care for patients with HCV genotype 1 infection in the United States and the European Union. Boceprevior- or telaprevir-based therapy significantly improved the SVR rate in naïve and experienced patients . Around 25~30% of HCV genotype 1 dually infected patients did not respond to Peg-IFN/RBV therapy . The value of new DAA-based triple therapy in this difficult-to-treat subgroup should be investigated soon. Whether IFN-free DAA-based therapy is effective in the control of HCV infection in dually infected patients is another interesting issue to be resoled. To be noted, in the latter scenario, IFN-free regimen would not be able to clear HBsAg.
Summary and future directions
HCV/HBV dual infection is not uncommon in areas endemic for HCV or HBV infection and among subjects at risk of parenteral transmission. Before the implementation of antiviral therapy, thorough serological and virological examinations are required to determine the viral dominance as well as to determine the optimal antiviral regimen. For dually infected patients with active hepatitis C, the same genotype-dependent treatment recommendations for single chronic hepatitis C still hold true [23-26]. However, for dually infected patients with active hepatitis B or with established cirrhosis [27,28], more studies are needed to determine the optimal regimen to treat both viruses at the same time. The value of DAA-based triple therapy in this population also remains to be clarified.
1. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005;104:783-791.
2. Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 2009;3:517-525.
3. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011;54:381-392.
4. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002;36:1285-1291.
5. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024-1029.
6. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
7. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643-3650.
8. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/ hepatitis B co-infection versus those with chronic hepatitis C monoinfection. Gastroenterology 2009;136:496-504.
9. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, et al. Sustained HCV clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology 2013;57:2135-2142.
10. Liu CJ, Chu YT, Shau WY, Kuo RNC, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon alfa and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2013 May 15. [Epub ahead of print]
11. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology 2006;43:100-107.
12. Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT et al. Ethnic differences in Accepted viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology 2011;53:1839-1845.
13. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-2977.
14. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-576.
15. Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-133.
16. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727-732.
17. Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha 2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-694.
18. Kim YJ, Lee JW, Kim YS, Jeong SH, Kim YS, Yim HJ, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol 2011;17:199-205. 1
9. Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011;6:e20752.
20. Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut 2013 Aug 6. doi: 10.1136/gutjnl-2013-305115. [Epubahead of print].
21. Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010:202:86-92.
22. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013;8:e53008.
23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
24. Omata M, Kanda T, Yu ML, Lim SG, Jafri W, Tateishi R, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35.
25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
26. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-561.
27. Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064-1065.
28. Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat 2012;19:890-896.
To view table and images go to PDF pp. 13-15